Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
MeSH Number(s)
D08.811.913.696.620.682.725.400.950
D12.776.543.750.060.750
D12.776.543.750.750.400.910
Concept/Terms
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Permeability Factor
- Vascular Endothelial Cell Growth Factor Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- VEGF Receptors
- Receptors, VEGF
- VPF Receptor
- Receptor, Vascular Endothelial Cell Growth Factor
- Vascular Permeability Factor Receptor
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 8 | 8 |
| 1996 | 0 | 9 | 9 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 9 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 15 | 15 |
| 2001 | 0 | 21 | 21 |
| 2002 | 0 | 18 | 18 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 5 | 10 |
| 2006 | 3 | 3 | 6 |
| 2007 | 5 | 8 | 13 |
| 2008 | 4 | 7 | 11 |
| 2009 | 4 | 15 | 19 |
| 2010 | 7 | 8 | 15 |
| 2011 | 4 | 9 | 13 |
| 2012 | 9 | 11 | 20 |
| 2013 | 8 | 9 | 17 |
| 2014 | 16 | 7 | 23 |
| 2015 | 14 | 5 | 19 |
| 2016 | 10 | 11 | 21 |
| 2017 | 8 | 8 | 16 |
| 2018 | 6 | 9 | 15 |
| 2019 | 8 | 8 | 16 |
| 2020 | 6 | 4 | 10 |
| 2021 | 1 | 14 | 15 |
| 2022 | 1 | 8 | 9 |
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Tivozanib for the treatment of advanced renal cell carcinoma. Expert Opin Pharmacother. 2022 Jul; 23(10):1135-1142.
-
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 08 25; 387(8):692-703.
-
TWO-YEAR RESULTS OF INTRAVITREAL INJECTIONS OF AFLIBERCEPT IN COATS DISEASE: A CASE REPORT. Retin Cases Brief Rep. 2022 Jul 01; 16(4):473-478.
-
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Rev Anticancer Ther. 2022 07; 22(7):695-702.
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. J Immunother Cancer. 2022 03; 10(3).
-
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial. Retina. 2022 06 01; 42(6):1111-1120.
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 02 19; 399(10326):729-740.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.